In the past 52-week period, shares of ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) have moved within the range of $0.25 to $4.27. On the stock’s most recent trading day, the company’s shares ended the regular session at $0.31, which is 92.74% higher than its 52-week high.
ImmunoCellular Therapeutics, Ltd. (IMUC) has demonstrated a 20-day simple moving average (SMA) of -11.30%, and a 50-day SMA of -14.34%. This public company’s current market capitalization stands at $4.76 million.Analyzing Consensus Estimates, Sales Revenue and Net Income
When thinking about buying shares in a public company, it is useful to gauge the average enthusiasm level of Wall Street analysts for that specific stock. According to the latest data, the consensus recommendation for ImmunoCellular Therapeutics, Ltd. (IMUC) is Hold.
When it comes to quarterly financial results, publicly-traded companies usually post earnings and revenue figures that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, ImmunoCellular Therapeutics, Ltd. (IMUC) delivered a 100.00% surprise with its net revenue.Ownership at ImmunoCellular Therapeutics, Ltd. (IMUC), According to Most Recent SEC Filings
Investors can gain useful insight on institutional ownership within a public company by taking a look at the organization’s most recent 13F filings. ImmunoCellular Therapeutics, Ltd. (IMUC) has 0 billion shares outstanding currently, 04.42% of which belong to institutional investors.
Additionally, according to the most recent 13F filing from ImmunoCellular Therapeutics, Ltd. (IMUC), there were 5 new positions totaling 159,833 shares of the company’s stock. There were 3 sold out positions, on the other hand, totaling 176 shares.Short, Medium and Long Term Indicators
By looking at a stock’s average trade volume – in the short, medium, and long terms – we can gain a better understanding of investor sentiment and trading activity. ImmunoCellular Therapeutics, Ltd. (IMUC) has had a 20-day average volume of 1,239,040 shares, with an average of 80% of short term indicators pointed at Sell.
The stock’s 50-day average volume has been 2,738,850 shares, with an average of 100% of medium term indicators pointing toward Sell. Finally, its 100-day average volume is 2,477,441 shares with 67% of long-term indicators pointing to Sell.